WESTFIELD, NJ--(Marketwired - June 03, 2014) - Relburn-Metabolomics, Inc., an emergent life-science company focused on improving health for patients with metabolic and inflammatory diseases, will update the Company's scientific and clinical progress at the 2014 European Congress on Rheumatology. EULAR, which is the principal EU scientific society for rheumatologic disorders, will hold its annual meeting at the Le Palais de Congrès, Porte Maillot, Paris from June 11-14, 2014. The review of recent results will be presented by Relburn's Chief Executive Officer, Dr. Raymond P. Warrell, Jr., at a poster session scheduled from 10:30AM to 12 Noon on Saturday, June 14. Relburn's lead program is focused on the development of disease-transforming therapy for patients with chronic gout.
Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on both the production and excretion sides of the uric acid equilibrium. Excessive amounts of uric acid in blood are associated with acutely painful and destructive arthritis, along with renal insufficiency and accelerated cardiovascular disease. Inhibitors of the enzyme, xanthine oxidase (such as allopurinol) that reduce uric acid production are standard first-line treatments; however, less than half of patients achieve potentially beneficial "target" levels (i.e., less than 6.0 mg/dL). Other monofunctional drugs can increase urinary uric acid excretion, but these drugs are generally no more potent than allopurinol and are relegated to second-line, add-on use.
Based on clinical discoveries by Relburn scientists, the Company has developed a series of exceptionally potent bifunctional compounds that both reduce uric acid production as well as promote its excretion. In clinical trials encompassing more than 350 patients, serum uric acid was routinely reduced to levels less than 1.0 mg/dL. Having established "clinical proof-of-concept," Relburn's Medicinal Chemistry program synthesized compound libraries with the objectives of elucidating mechanisms of action, enhancing clinical potency, and reducing potential side-effects. The Company has discovered a series of first-in-class compounds that meet these objectives and that are covered by patent applications exclusively owned by Relburn. Relburn believes monotherapy with its compounds can potentially replace standard first-line treatments and meaningfully improve clinical outcomes for patients with chronic gout.
Further information about Relburn-Metabolomics, Inc. can be accessed here: www.relburn.com. Information about the EULAR 2014 meeting is available here: http://www.eular.org/index.cfm?framePage=/congress_2014.cfm.
This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially," "anticipates," "expects," and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.
SOURCE: Relburn-Metabolomics™ Inc.